HitGen Inc
SSE:688222
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
HitGen Inc
SSE:688222
|
CN |
|
Genesis Energy LP
NYSE:GEL
|
US |
|
China Tower Corp Ltd
HKEX:788
|
CN |
|
Ymirlink Inc
TSE:4372
|
JP |
|
H
|
HCA Healthcare Inc
SWB:2BH
|
US |
|
Alvo Minerals Ltd
ASX:ALV
|
AU |
|
Jbm (Healthcare) Ltd
HKEX:2161
|
HK |
|
J
|
Jiangsu Hongtu High Technology Co Ltd
SSE:600122
|
CN |
HitGen Inc
HitGen, Inc. engages in the provision deoxyribonucleic acid encoded compound library (DEL) for research and development of seed and lead compounds. The company is headquartered in Chengdu, Sichuan and currently employs 508 full-time employees. The company went IPO on 2020-04-16. The firm focuses on the research and creation of deoxyribonucleic acid encoded compound library (DEL) technology, research and development of hit compounds and lead compounds. The firm mainly provides DEL screening services, DEL library customization services, chemical synthesis services and transfer of new drug research and development projects. The firm conducts its businesses within the domestic market and to overseas markets.
HitGen, Inc. engages in the provision deoxyribonucleic acid encoded compound library (DEL) for research and development of seed and lead compounds. The company is headquartered in Chengdu, Sichuan and currently employs 508 full-time employees. The company went IPO on 2020-04-16. The firm focuses on the research and creation of deoxyribonucleic acid encoded compound library (DEL) technology, research and development of hit compounds and lead compounds. The firm mainly provides DEL screening services, DEL library customization services, chemical synthesis services and transfer of new drug research and development projects. The firm conducts its businesses within the domestic market and to overseas markets.
